FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283370300> ?p ?o ?g. }

• W4283370300 endingPage "1682" @default.
• W4283370300 startingPage "1661" @default.
• W4283370300 abstract "Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-acting antiviral (DAA) therapy approved for patients who have previously failed a DAA-containing regimen including NS5A inhibitors. In clinical trials, SOF/VEL/VOX was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. However, the effectiveness and safety of SOF/VEL/VOX in the real world remained uncertain. We aimed to perform a systematic review and meta-analysis to assess the real world effectiveness and safety of SOF/VEL/VOX.We systematically searched the PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov databases for relevant real world studies published before January 28, 2022. Patients with previous treatment failure who received SOF/VEL/VOX were included. The primary outcome was the percentage of patients achieving SVR12. Secondary outcome included adverse events (AEs) during treatment.Fifteen studies with a total of 1796 HCV-infected patients with previous treatment failure were included. SVR12 rates were 93% (95% CI 91-95) in the ITT populations (n = 1517, 11 cohorts) and 96% (95% CI 95-97) in the PP populations (n = 1187, 10 cohorts). SVR12 rates were significantly higher in non-GT3-infected patients (OR = 2.29, 95% CI 1.23-4.27, P = 0.009) and non-cirrhotic patients (OR = 2.22, 95% CI 1.07-4.60, P = 0.03) than in GT3-infected patients and cirrhotic patients. Furthermore, the SVR12 rates of previous treatment of SOF/VEL were significantly lower than those of other regimens in both ITT and PP populations (P ≤ 0.001). Adverse events (AEs) were reported in 30% (228/760) of patients. Serious AEs (SAEs) were reported in 3.82% (29/760) of patients. The most frequently reported AEs were headache, asthenia, nausea, fatigue, and diarrhea, which were mostly mild in severity. AE-related treatment discontinuations were reported in 0.66% (5/760) of patients.Consistent with clinical trials, the real world evidence indicates that SOF/VEL/VOX is a well-tolerated and highly effective salvage therapy for HCV-infected patients with previous treatment failure. However, there may still be a risk of treatment failure for patients with GT3 infection, cirrhosis, or SOF/VEL treatment failure. The protocol of this study was registered at PROSPERO, registration no. CRD 42022306828." @default.
• W4283370300 created "2022-06-25" @default.
• W4283370300 creator A5013913588 @default.
• W4283370300 creator A5018323072 @default.
• W4283370300 creator A5033957340 @default.
• W4283370300 creator A5071037763 @default.
• W4283370300 creator A5087469214 @default.
• W4283370300 date "2022-06-24" @default.
• W4283370300 modified "2023-09-30" @default.
• W4283370300 title "Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis" @default.
• W4283370300 cites W1964435302 @default.
• W4283370300 cites W2139252405 @default.
• W4283370300 cites W2157294800 @default.
• W4283370300 cites W2157823046 @default.
• W4283370300 cites W2185218296 @default.
• W4283370300 cites W2289667014 @default.
• W4283370300 cites W2345381660 @default.
• W4283370300 cites W2492023951 @default.
• W4283370300 cites W2515727544 @default.
• W4283370300 cites W2531269403 @default.
• W4283370300 cites W2605116305 @default.
• W4283370300 cites W2617500612 @default.
• W4283370300 cites W2805861778 @default.
• W4283370300 cites W2886511433 @default.
• W4283370300 cites W2889750687 @default.
• W4283370300 cites W2890778396 @default.
• W4283370300 cites W2937510843 @default.
• W4283370300 cites W2942192762 @default.
• W4283370300 cites W2944132895 @default.
• W4283370300 cites W2944976706 @default.
• W4283370300 cites W2951737729 @default.
• W4283370300 cites W2966216116 @default.
• W4283370300 cites W3006658062 @default.
• W4283370300 cites W3009290908 @default.
• W4283370300 cites W3017962877 @default.
• W4283370300 cites W3028341895 @default.
• W4283370300 cites W3034196241 @default.
• W4283370300 cites W3037650011 @default.
• W4283370300 cites W3045987563 @default.
• W4283370300 cites W3047835683 @default.
• W4283370300 cites W3083532209 @default.
• W4283370300 cites W3087725377 @default.
• W4283370300 cites W3092753669 @default.
• W4283370300 cites W3116147819 @default.
• W4283370300 cites W3118615836 @default.
• W4283370300 cites W3133598554 @default.
• W4283370300 cites W3163278809 @default.
• W4283370300 cites W3169832432 @default.
• W4283370300 cites W3186670979 @default.
• W4283370300 cites W3200673479 @default.
• W4283370300 cites W3203303739 @default.
• W4283370300 cites W4205359295 @default.
• W4283370300 cites W4206635732 @default.
• W4283370300 cites W4214725675 @default.
• W4283370300 cites W4252015434 @default.
• W4283370300 cites W971519378 @default.
• W4283370300 doi "https://doi.org/10.1007/s40121-022-00666-0" @default.
• W4283370300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35749010" @default.
• W4283370300 hasPublicationYear "2022" @default.
• W4283370300 type Work @default.
• W4283370300 citedByCount "11" @default.
• W4283370300 countsByYear W42833703002022 @default.
• W4283370300 countsByYear W42833703002023 @default.
• W4283370300 crossrefType "journal-article" @default.
• W4283370300 hasAuthorship W4283370300A5013913588 @default.
• W4283370300 hasAuthorship W4283370300A5018323072 @default.
• W4283370300 hasAuthorship W4283370300A5033957340 @default.
• W4283370300 hasAuthorship W4283370300A5071037763 @default.
• W4283370300 hasAuthorship W4283370300A5087469214 @default.
• W4283370300 hasBestOaLocation W42833703001 @default.
• W4283370300 hasConcept C126322002 @default.
• W4283370300 hasConcept C197934379 @default.
• W4283370300 hasConcept C203014093 @default.
• W4283370300 hasConcept C2522874641 @default.
• W4283370300 hasConcept C2776408679 @default.
• W4283370300 hasConcept C2776455275 @default.
• W4283370300 hasConcept C2776478404 @default.
• W4283370300 hasConcept C2778390639 @default.
• W4283370300 hasConcept C2780040827 @default.
• W4283370300 hasConcept C2781413609 @default.
• W4283370300 hasConcept C71924100 @default.
• W4283370300 hasConcept C95190672 @default.
• W4283370300 hasConceptScore W4283370300C126322002 @default.
• W4283370300 hasConceptScore W4283370300C197934379 @default.
• W4283370300 hasConceptScore W4283370300C203014093 @default.
• W4283370300 hasConceptScore W4283370300C2522874641 @default.
• W4283370300 hasConceptScore W4283370300C2776408679 @default.
• W4283370300 hasConceptScore W4283370300C2776455275 @default.
• W4283370300 hasConceptScore W4283370300C2776478404 @default.
• W4283370300 hasConceptScore W4283370300C2778390639 @default.
• W4283370300 hasConceptScore W4283370300C2780040827 @default.
• W4283370300 hasConceptScore W4283370300C2781413609 @default.
• W4283370300 hasConceptScore W4283370300C71924100 @default.
• W4283370300 hasConceptScore W4283370300C95190672 @default.
• W4283370300 hasIssue "4" @default.
• W4283370300 hasLocation W42833703001 @default.
• W4283370300 hasLocation W42833703002 @default.
• W4283370300 hasLocation W42833703003 @default.

• next